Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
High-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and is one of the most intriguing molecules in inflammatory disorders and cancers. Notably, HMGB1 is a potential therapeutic target and novel biomarker in related diseases. However, the diagnostic value of HMGB1 for benign and malignant asbestos-related diseases (ARDs) remains unclear. In this work, we detected preoperative serum HMGB1 levels in Chinese asbestos-exposed (AE) and ARDs populations and further evaluated the diagnostic value of HMGB1 in patients with certain types of ARDs, including those with pleural plaques, asbestosis, or malignant mesothelioma (MM). The experimental data presented that the serum level of HMGB1 was significantly elevated in AE and ARDs subjects. Our findings indicated that serum HMGB1 is a sensitive and specific biomarker for discriminating asbestosis- and MM-affected individuals from healthy or AE individuals. In addition, serum matrix metalloproteinases 2 and 9 are not correlated with HMGB1 in ARDs. Thus, our study provides supporting evidence for HMGB1 as a potential biomarker either for the clinical diagnosis of high-risk AE cohorts or for evaluating ARDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“High levels in the blood of both subjects exposed to asbestos and mesothelioma patients have been demonstrated [62].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436 · cited 2×
“Increasing clinical evidence indicates that extracellular HMGB1 contributes to inflammatory disorders and cancer development [5, 6, 32].”
BackgroundMatrix metalloproteinases (MMPs): Chemical–biological functions and (Q)SARs
Verma, R. P., & Hansch, C. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.011 · Cited by 783 · cited 1×
“It is well known that MMPs are involved in the process of metastasis formation and that their overexpression correlates with the processes of tumor cell invasion and metastasis in human cancers by degrading the extracellular matrix [45, 46].”
BackgroundHigh-mobility group box 1 and cancer
Tang, D., Kang, R., Zeh III, H. J., & Lotze, M. T. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.014 · Cited by 512
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Cathcart, J., Pulkoski-Gross, A., & Cao, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.12.002 · Cited by 504 · cited 1×
“It is well known that MMPs are involved in the process of metastasis formation and that their overexpression correlates with the processes of tumor cell invasion and metastasis in human cancers by degrading the extracellular matrix [45, 46].”
BackgroundHMGB1 in Cancer: Good, Bad, or Both?
Kang, R., Zhang, Q., Zeh, H. J., Lotze, M. T., & Tang, D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0495 · Cited by 493
Husain, A. N., Colby, T., Ordonez, N., Krausz, T., Attanoos, R., Beasley, M. B., Borczuk, A. C., Butnor, K., Cagle, P. T., Chirieac, L. R., et al. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0214-oa · Cited by 473 · cited 1×
“MPM was diagnosed by at least two independent pathologists according to the Guidelines for Pathologic Diagnosis of Malignant Mesothelioma proposed by the International Mesothelioma Interest Group [25].”
MethodAn overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, D., Roviello, G. N., & Montesarchio, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.001 · Cited by 334 · cited 1×
“Novel strategies targeting HMGB1, such as glycyrrhizin [37], gabexate mesilate [37], ethyl pyruvate [38, 39], and PPAR ligands [40] that interfere with asbestos-mediated inflammation, may prevent or delay ARDs onset and relieve the progress of malignant ARDs.”
BackgroundYang, H., Rivera, Z., Jube, S., Nasu, M., Bertino, P., Goparaju, C., Franzoso, G., Lotze, M. T., Krausz, T., Pass, H. I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006542107 · Cited by 281
Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma
Jube, S., Rivera, Z. S., Bianchi, M. E., Powers, A., Wang, E., Pagano, I., Pass, H. I., Gaudino, G., Carbone, M., & Yang, H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3481 · Cited by 255 · cited 2×
“One group from the USA provided the first evidence that HMGB1 was highly expressed in both tissues and sera of mesothelioma patients [20].”
BackgroundDiagnosis and Initial Management of Nonmalignant Diseases Related to Asbestos
Smith, D. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.171.6.951 · Cited by 252
Cited by
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Opitz, I., Scherpereel, A., Berghmans, T., Psallidas, I., Glatzer, M., Comas, D. R., Astoul, P. J., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaa158 · Cited by 121
Epidemiology of Environmental Exposure and Malignant Mesothelioma
Liu, B., van Gerwen, M. A. G., Bonassi, S., & Taioli, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.002 · Cited by 118
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Chen, Z., Gaudino, G., Pass, H. I., Carbone, M., & Yang, H. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.05.06 · Cited by 95
“Consistently, we found that HMGB1 levels in serum and plasma were higher in MM patients compared to healthy individuals (Figure 1) (78) and these findings were confirmed by other studies reporting significantly higher serum HMGB1 levels in MM patients compared to individuals with benign asbestos-related diseases (79,8…”
ResultBiomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
Ledda, C., Senia, P., & Rapisarda, V. (2018) · Cancers · doi:10.3390/cancers10060203 · Cited by 62
“Scientific studies have shown that HMGB1 serum levels are higher in MM patients than in asbestos-only controls (not affected by MM) [78].”
Background
Metadata
- Authors
- Ying, S., Jiang, Z., He, X., Yu, M., Chen, R., Chen, J., Ru, G., Chen, Y., Chen, W., Zhu, L., Li, T., Zhang, Y., Guo, X., Yin, X., Zhang, X., & Lou, J.
- Affiliations
- Zhejiang Academy of Medical Sciences (CN)
- Zhejiang Provincial People's Hospital (CN)
- Jiading District Center for Disease Control and Prevention, Shanghai 201800, China
- Corresponding author
- Lou, Jianlin
- ORCID
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-9
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- PMC
- PMC5350493
- OpenAlex
- W2593453675
- Cited by
- 54
- References
- 48
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 11 · 2019: 7 · 2018: 6 · 2017: 3
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Disease Markers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Natural Science Foundation of Zhejiang Province (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Qianjiang Talents Project of Zhejiang Province (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- National Natural Science Foundation of China (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Health and Family Planning Commission of Zhejiang Province (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Zhejiang Committee of Science and Technology (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Keywords
- HMGB1, asbestos-related diseases, serum biomarkers, asbestos exposure, asbestosis, malignant mesothelioma, pleural plaques, MMP-2, MMP-9, diagnostic value, inflammation
- MeSH terms
- Mesothelioma, Malignant, Aged, Asbestosis, Female, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Biomarkers, Tumor, Case-Control Studies, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, HMGB1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases. https://app.cochat.ai/papers/10.1155/2017/5756102
- The paper
- Ying, S., Jiang, Z., He, X., Yu, M., Chen, R., Chen, J., Ru, G., Chen, Y., Chen, W., Zhu, L., Li, T., Zhang, Y., Guo, X., Yin, X., Zhang, X., & Lou, J. (2017). Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases. Disease Markers. https://doi.org/10.1155/2017/5756102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.